Categories

Above the Fold

POLICY: Too many physicians? UPDATE midday Friday

We’ve been told by COGME no less that there’s an impending physician shortage, and today I reviewed a whole bunch of material for a hospital that looked like it was true.  However, to put a spike in this balloon, an article published online in Health Affairs by Jonathan Wiener showed that even with extra recruitment over the 1990’s, the large prepaid group practices like Kaiser and HealthPartners still managed to serve their populations with far fewer physicians per 1,000 patients than already exist in the US, let alone the number that will be practicing in 20 years time. And all this with physicians allegedly working shorter hours and seeing fewer patients than in the wider FFS world.

I’ll update my thoughts about this later (It’s late and I just got off the plane!) BUT go give the article a read.

UPDATE. OK I’m off my 3 hours early morning call and can spend a moment extending this post, especially as it has a passing relevance to the project I’m working on.  Here’s the argument:

Way back in the early 1990s those forecasting the physician workforce made some assumptions that the US would move closer to gatekeeper/managed care model.  This type of a model assumed a split between specialists and generalists that’s close to 50-50, and in many countries it’s closer to 20-80.  The model also assumed that there would be fewer surgeries and procedures as the model unfurled.  At that point consultants wondering around with bed days per enrollee of Medicare managed care plans in southern California became a familiar feature of the hospital boardroom (yes, I admit I was one of them).  Essentially if you played out that model nation-wide we had about 75% too many hospitals and a few too few generalists and 50% too many specialists. That future never happened for a variety of reasons, mostly connected with the death of managed care. However we did see a reduction in the number of residency slots, including some teaching hospitals being paid to not train residents.

Instead we started seeing a rash of new procedures and technologies, especially in the unmanaged Medicare population, and the newly unmanaged HMO-lite population. Meanwhile there was a rash of hospital consolidation and bed reduction in the 1990s (although only about 10%). Then the prognositcators started to notice the impending arrival of the baby boom, the leading edge of which hits 60 next year and Medicare in 2010.  So we can do more things to more people and will have an increasing number of people to do them to. They also noticed that medical school applications had fallen (although not the number of those in med school, just fewer candidates for each place) and some surveys showed that most physicians wouldn’t recommend medicine as a career to a new student.  Yet we didn’t fundamentally change our system in the last two decade. So about a couple of years ago you started seeing articles like this one warning that we had a shortage coming and that we needed more doctors, and in fact late last year COGME recommended that we increase the level of residency slots 15%.

Weiner’s article simply points out that we can give appropriate care to a given population with a physician-to-population ratio that is 22-37% below the current national rate.  How do the bigger PGPs do it?  Not apparently by working their doctors harder–in fact they probably work fewer hours. Not by adding more primary care doctors–over the years primary care doc numbers in these groups grew less slowly than those of specialists, although the share of primary care docs remains higher than in the overall physician population. In fact specialty position growth in these PGPs exceeded that of the national average. Instead they use more physician extenders (nurse practitioners and physician assistants) for between 17% and 25% of primary care providers–as opposed to the 10% they represent in the overall primary care provider population. Kaiser in particular uses specialty care nurse practitioners–their growth was 16% annually in the 1990s. They also use more preventative care and disease management programs, probably work their procedural specialists harder (this is certainly the case abroad), and probably do less surgery

Meanwhile Solucient projects strong demand for cardiologists, GI and orthopedics docs while the folks at the Advisory Board (who’ve been known to extend a chart line well beyond breaking point in their time–anyone remember their forecast of 90% capitation by 2005?) believe that there’ll be a shortfall in specialist hours of between 35% for intensivists and up to 70% for cardiologists by 2030. They also have a neat chart in their recent report on physicians which correlates GDP per head in the US with MDs per thousand — in other words the richer we get the more money we want to spend on doctors? (Well that’s one interpretation!)

So how will this play out?  One thing to remember is that thanks to the expansion of med schools in the 1960s and 1970s we are still pumping out docs out of residency programs at about the rate of 20,000 a year, with only about 8,000 a year retiring, and that growth will continue until about 2015.  So the number of active non-federal doctors per 100,000 population, which is about 225 now, will peak at 235 in 2010 and only fall back to 230 in 2020. In a chart which includes NPs and PAs, Wiener shows that while the US now has a total of 230 MDs, DOs, NPs and PAs per 100,000, the big PGPs get by with 145-175. So although the rest of US health care lives in a different world than Kaiser and Group Health, anyone wanting more money for medical school and residency places is going to have to make a pretty convincing argument that they’re really needed–especially with $500 billion deficits out as far as the eye can see.  So, as it takes 8-10 years for a policy change to show up as the first "additional" doc in practice, I believe we’ll work with what we’ve got at least out until 2030 and probably beyond.

Medicare will inevitably have to slowly change its payment arrangementss to reflect this–although that’ll be a touch battle. Private plans are already working on similar ideas, such as pay for performance, and the folks at Leapfrog and IOM are also pushing for changes in the model of care delivery. So slowly over time expect the obvious:

–More use of phsyician extenders, such as other clinical professionals. 
–More and better use of technology to make physicians more efficient and patients better at self-care
–Innovative patient-centered practices that get around the "broken chassis" of the 8 minute office visit, and require less physician intervention
–Longer waits (eventually) for the real hard-core sub-specialists, higher salaries for those guys and more struggles between hospitals for the revenue generating superstars.
–Concominant rationing of the really expensive stuff. Don’t worry–you wouldn’t be able to afford it by then anyway!

TECHNOLOGY: Boston Scientific’s new stent near market

Boston Scientific is having a good run.  Its sales are up and its new drug-eluting stent Taxus, which has been doing well outside the US, is close to approval here.  J&J’s Cypher stent is likely to be the main loser when Taxus is approved here, but the arms race between these two and Guidant will continue.  Of course everyone’s ignoring what the Stanford study said about the value of these stents last year.

Boston Scientific’s stock is up nearly 30% in the last 3 months.

PHARMA: Public Image continues to go downhill

You may remember the story from the Industry Veteran a few weeks back about the massive price increase in Abbot’s HIV drug, Norvir. Well the Sacramento Bee notes that things are close to going thermonuclear now.

    In a Jan. 20 letter to the company, more than 150 doctors who specialize in HIV care said they will resign from Abbott advisory panels, refuse to participate in Abbott drug trials or attend Abbott-sponsored lectures. They will ban Abbott representatives from their offices and consider alternatives to Abbott drugs when possible for their patients.

Also today there was an editorial in Eye for Pharma which suggested that the reason for pharma’s poor levels of public trust were to do with its opaque practices:

    Perhaps the industry simply hasn’t revealed enough of its inner workings to adequately earn the public’s trust. What lurks behind the manicured lawns and lights in the windows of pharma campuses is largely a mystery to most of our customers.

    There is no easy answer. But maybe it’s a matter of working hard to push the black curtain aside and help the public better understand complicated matters like R&D costs and effort and how that translates to retail drug prices. Perhaps "open houses" and public outreach events would give the communities we live and work in a glimpse of the "inside" of pharma.

 Nice try, but it’s price gouging like the Norvir incident and the blocking of imports from Canada that is really riling the public.  And this is in advance of the Democrats taking on the Medicare bill as a big give away to Pharma. MoveOn is already starting to run those ads, that clamor is sure to grow.  If I was in pharma, I’d be quickly thinking about what good things I could do to improve my image.  Enhanced DSM and drug programs for poor kids might be one place to start and publicize what was being done.

PHARMA/GENOMICS: Incyte throws in the towel

When I went to a conference on Genomics at Northwestern University in 1997 there was great excitement that the human genome project was going to be finishing quicker than anticipated.  There was also widespread controversy that one company, Incyte Pharmaceuticals, had patented a vast number of genes, or at least the ability to do anything with them–the academics in Chicago were worried about the effect this would have on their research.  Incyte’s business was based on selling its library of genes to pharma companies for their R&D. A couple of years after that Incyte’s stock got caught up in the 1999-2000 craziness and at one point the company was worth $25 billion, give or take a billion. 

But soon a combination of Craig Ventner’s Celera Genomics joining the gene sequencing arms race and the increased public domain access to genetic information brought that business back to earth.  Yesterday Incyte shuttered its Palo Alto offices and with it the proprietary genomic data product lines, LifeSeq and ZooSeq and will concentrate on its own drug development work instead. Its market cap is now back below $1 billion and actually looks generous at this level.

HEALTH PLANS: For-profit conversions don’t really leave anyone Blue

Apologies for the appalling pun, but HSC is out with a very thorough and readable analysis of the for-profit conversion of many Blues plans, and what the impact of these conversions has been.  They note that virtually all the converted Blues are ending up in one big organization (the new Anthem) and their conclusion pretty much matches my opinion–it doesn’t really make any difference whether the Blues are for-profit or not, they always acted the same way (i.e. like a health insurer!).  But on the other hand the amount of money gained by the states or Foundations that resulted from the conversions is more than enough to exhaustively study all of health care’s problems. It’s just not enough to actually solve any of them.

Ouch! Internal Bleeding exposes medical errors

Modern Physician has an interview with Bob Wachter, who’s new book is called Internal Bleeding. There are something in the region of 20 odd medical errors written up in the book, with a view to showing the system problems behind them.  This is something of an old story, and Michael Millenson’s Demanding Medical Excellence gave a great account of the overall safety/quality environment a few years back.  But the more the story can be told the better the chance that the battleship will be turned in the direction of safer medical care. In fact several large health organizations are actively working on these programs, such as Ascension’s Healthcare that’s safe.

QUALITY QUICKIE: EBM goes mainstream (sort of)

With a hat-tip to Lisa Williams, this month’s Atlantic Monthly Journal has the first article I’ve ever seen in a mainstream magazine on EBM. The author calls for a national clinical institute to supplant the NIH and AHCQ, and actually make pronouncements on what works, and try to get the medical profession and health care industry to follow it. I’m so knocked out by an article on this topic getting into a major non-health care journal, that it would churlish to point out that our British cousins have already got one.

POLICY: Health savings accounts-the likely impact

Over at Medpundit, Sydney Smith quotes the WSJ on health care cost breakdowns and argues that HSAs will allow market intervention in the share of spending that goes to doctors and pharmaceuticals, and will bring both that spending under control and enforce market discipline on the providers to give us stuff we want.  The WSJ thinks that what the consumer wants is flash computer-based customer service and they may well be right. There are though a couple of problems with this, and it takes a nerdy wonk like me to point them out. First, it’s unclear exactly what the HSA can be used to pay for (OTC drugs? I doubt it; off formulary drugs? Maybe not in Medicare) so there’ll be less of a market in which it can enforce its discipline than might be suspected. Second, about half of physician costs are connected to other costs that involve hospital stays and surgery–in other words they happen after the deductible has already been blown and the HSA spent, and we’re not talking about 33% of spending but more like 20-odd % of the "market" being "managed" by these new HSA bearing consumers–and that’s assuming that everyone gets one.  The real issue as George Halvorson points out and Milton Friedman despite his many intelligent view points gets wrong is that almost 70% of the money goes on 10% of the people.  That’s where the costs need to be controlled, and there’s nothing in the HSA that can possibly do anything about that.

Now from the other side of my mouth, here’s why I’m getting one.  I pay my own insurance and I have medical expenses that don’t reach my deductible and I’d love to pay those in pre-tax versus post-tax dollars. So for people like me, they’ll grow as a niche insurance product. But I’m only 8% of the market.  64% are in employer-based insurance and they’re beginning to flirt with consumer-directed health plans. Some of these consumer-directed health plans give  money to the employees to put in their HSA. Once employers figure out that giving real money to employees for their HSA’s means taking it away from their self-insurance pool, they’ll either find the next trendy product OR reduce markedly the amount they give so that it is way less than the deductible.  At that point all but the healthiest employees will move back to a more comprehensive plan.

Meanwhile Sydney will have to figure out why she’s creating a understandable consumer price list–and that’s not simply printing out the CPT codes– just for the 10% of patients walking into her office who are now paying with pre-tax but real dollars. My advice is to her is to mark those prices up!

assetto corsa mods